Corvus Pharmaceuticals’ (CRVS) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Corvus Pharmaceuticals (NASDAQ:CRVSGet Rating)‘s stock had its “overweight” rating reissued by stock analysts at Cantor Fitzgerald in a note issued to investors on Wednesday, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Corvus Pharmaceuticals’ FY2022 earnings at ($0.69) EPS and FY2023 earnings at ($0.76) EPS.

Separately, StockNews.com started coverage on shares of Corvus Pharmaceuticals in a report on Friday, July 1st. They set a “sell” rating on the stock.

Corvus Pharmaceuticals Stock Performance

Shares of CRVS stock opened at $0.78 on Wednesday. The company has a market capitalization of $36.31 million, a P/E ratio of -0.97 and a beta of 0.90. The company’s 50 day moving average price is $0.96 and its two-hundred day moving average price is $1.17. Corvus Pharmaceuticals has a 52 week low of $0.75 and a 52 week high of $8.11.

Corvus Pharmaceuticals (NASDAQ:CRVSGet Rating) last announced its earnings results on Monday, August 8th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.19) by $0.01. Analysts forecast that Corvus Pharmaceuticals will post -0.96 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the business. State Street Corp raised its stake in Corvus Pharmaceuticals by 12.2% during the first quarter. State Street Corp now owns 112,603 shares of the company’s stock worth $185,000 after acquiring an additional 12,203 shares in the last quarter. Coastal Bridge Advisors LLC acquired a new position in Corvus Pharmaceuticals during the fourth quarter worth about $58,000. Hikari Power Ltd raised its stake in Corvus Pharmaceuticals by 150.3% during the first quarter. Hikari Power Ltd now owns 49,959 shares of the company’s stock worth $82,000 after acquiring an additional 30,000 shares in the last quarter. Vanguard Group Inc. raised its stake in Corvus Pharmaceuticals by 2.9% during the first quarter. Vanguard Group Inc. now owns 1,267,752 shares of the company’s stock worth $2,079,000 after acquiring an additional 36,002 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in Corvus Pharmaceuticals by 72.6% during the first quarter. Acadian Asset Management LLC now owns 140,118 shares of the company’s stock worth $228,000 after acquiring an additional 58,952 shares in the last quarter. Institutional investors and hedge funds own 55.02% of the company’s stock.

Corvus Pharmaceuticals Company Profile

(Get Rating)

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers.

Further Reading

Receive News & Ratings for Corvus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corvus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.